Volume 87, Issue 1, Pages (January 2015)

Slides:

Advertisements

Similar presentations

Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy Francesco Paolo Schena Kidney International Volume 57,

Advertisements

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Ischemic heart disease after renal transplantation

LDL cholesterol in CKD—to treat or not to treat?

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Mitchell H. Rosner, W. Kline Bolton Kidney International

End-stage renal disease in developing countries

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Volume 79, Issue 9, Pages (May 2011)

Volume 83, Issue 3, Pages (March 2013)

Lipopheresis in the nephrotic syndrome

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Stem cells for kidney repair: useful tool for acute renal failure?

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan

Prehypertension and chronic kidney disease: the ox or the plow?

John P. Middleton, Patrick H. Pun Kidney International

Volume 77, Issue 1, Pages 6-8 (January 2010)

Burden of chronic kidney disease: North Africa

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Need for better diabetes treatment for improved renal outcome

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Homocysteine and risk in end-stage renal disease: a matter of context

Ian H. de Boer, Rajnish Mehrotra Kidney International

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Lipid redistribution in renal dysfunction

Volume 70, Issue 11, Pages (December 2006)

Gary C.W. Chan, Sydney C.W. Tang Kidney International

Volume 87, Issue 2, Pages (February 2015)

Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: agent provocateur or innocent bystander? Cecile Courivaud, Andrew.

Study of Heart and Renal Protection (SHARP)

LDL cholesterol in CKD—to treat or not to treat?

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Blood pressure targets in hemodialysis patients

Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House

Fructose intake as a risk factor for kidney stone disease

Volume 73, Issue 12, Pages (June 2008)

Volume 76, Issue 6, Pages (September 2009)

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

The kidney, a cardiovascular risk marker, and a new target for therapy

Atrial fibrillation in end-stage renal disease: an emerging problem

Volume 67, Issue 4, Pages (April 2005)

Nephrology Crossword: Glomerulonephritis

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Unilateral renal cystic disease

Circadian regulation of renal function

Volume 73, Issue 9, Pages (May 2008)

Mediterranean diets: are they practical in the Western world?

Volume 82, Issue 9, Pages (November 2012)

Cardio-Kidney-Damage: a unifying concept

Does equal care give equal outcomes?

Volume 80, Issue 10, Pages (November 2011)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Is it the low-protein diet or simply the salt restriction?

Is complement a target for therapy in renal disease?

Tobias Breidthardt, Alexandre Mebazaa, Christian E. Mueller

Volume 75, Issue 7, Pages (April 2009)

James B. Young, Hans-Hellmut Neumayer, Robert D. Gordon

Ischemic heart disease after renal transplantation

Hisataka Kobayashi, Peter L. Choyke Kidney International

Volume 70, Issue 10, Pages (November 2006)

Hemodialysis access failure: a call to action—revisited

Wendy E. Hoy, Megan Rees, Emma Kile, John D. Mathews, Zhiqiang Wang

Volume 74, Issue 10, Pages (November 2008)

Lipoprotein abnormalities in diabetic nephropathy

Presentation transcript:

Volume 87, Issue 1, Pages 243-244 (January 2015) Corrections to "Microalbuminuria: target for renoprotective therapy PRO" Kidney International Volume 87, Issue 1, Pages 243-244 (January 2015) DOI: 10.1038/ki.2014.321 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 4 Albuminuria, blood pressure, and low-density lipoprotein (LDL) cholesterol reduction predict renal or cardiovascular protection. Reduction in end-stage renal disease (a), heart failure (b), or vascular events (c) consequent to albuminuria reduction (a), blood pressure reduction (b), or LDL cholesterol reduction (c). Kidney International 2015 87, 243-244DOI: (10.1038/ki.2014.321) Copyright © 2015 International Society of Nephrology Terms and Conditions